The announcement of positive data on ibezapolstat, particularly its effects on the gut microbiome and potential in treating C. difficile, is likely to boost investor confidence in Acurx Pharmaceuticals. Additionally, the drug's efficacy against resistant B. anthracis could open new market opportunities, potentially driving the stock price up in the short term.